{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:25:08Z","timestamp":1774862708326,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["SIMM0120234003"],"award-info":[{"award-number":["SIMM0120234003"]}],"id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmcl.2024.129942","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T17:00:31Z","timestamp":1725037231000},"page":"129942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease"],"prefix":"10.1016","volume":"112","author":[{"given":"Wen","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiguo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129942_b0005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1631\/jzus.B2000083","article-title":"An overview of COVID-19","volume":"21","author":"Shi","year":"2020","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.bmcl.2024.129942_b0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.129942_b0015","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2024.129942_b0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2024.129942_b0025","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1002\/jmv.27643","article-title":"The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant","volume":"94","author":"Tian","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.bmcl.2024.129942_b0030","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: drug targets and potential treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129942_b0035","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129942_b0040","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129942_b0045","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2024.129942_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173375","article-title":"Virology, pathogenesis, diagnosis and in-line treatment of COVID-19","volume":"883","author":"Samudrala","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmcl.2024.129942_b0055","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1021\/acs.jmedchem.2c00404","article-title":"Evolutionary and structural insights about potential SARS-CoV-2 evasion of nirmatrelvir","volume":"65","author":"Yang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129942_b0060","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.bmcl.2024.129942_b0065","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2024.129942_b0070","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmcl.2024.129942_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13181-022-00922-2","article-title":"Tacrolimus drug-drug interaction with nirmatrelvir\/ritonavir (Paxlovid\u2122) managed with phenytoin","volume":"19","author":"Sindelar","year":"2023","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.bmcl.2024.129942_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103799","article-title":"The expanding repertoire of covalent warheads for drug discovery","volume":"28","author":"Mehta","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2024.129942_b0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.129942_b0090","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129942_b0095","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2024.129942_b0100","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1021\/acs.jmedchem.1c00665","article-title":"3CL protease inhibitors with an electrophilic arylketone moiety as anti-SARS-CoV-2 agents","volume":"65","author":"Konno","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129942_b0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41564-022-01119-7","article-title":"An orally available M(pro) inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron","volume":"7","author":"Quan","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmcl.2024.129942_b0110","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1002\/anie.202016961","article-title":"Targeting the main protease of SARS-CoV-2: from the establishment of high throughput screening to the design of tailored inhibitors","volume":"60","author":"Breidenbach","year":"2021","journal-title":"Angew Chem (International ed. in English)"},{"key":"10.1016\/j.bmcl.2024.129942_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115761","article-title":"Elemental exchange: bioisosteric replacement of phosphorus by boron in drug design","volume":"260","author":"Mehta","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129942_b0120","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2024.129942_b0125","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bmcl.2024.129942_b0130","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bmcl.2024.129942_b0135","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1021\/jacs.0c07433","article-title":"Next-generation total synthesis of vancomycin","volume":"142","author":"Moore","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2024.129942_b0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025866118","article-title":"Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing","volume":"118","author":"He","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2024.129942_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbrc.2021.02.016","article-title":"EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro","volume":"547","author":"Jang","year":"2021","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24003445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T21:45:18Z","timestamp":1726350318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24003445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"alternative-id":["S0960894X24003445"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129942","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129942"}}